Testing effectiveness (Phase 2)Looking for participantsNCT06220487
What this trial is testing
A Single-arm, Open-label Study of Olverembatinib, CD3/CD19 Bispecific T-cell Engager, and Chidamide in Patients With Newly Diagnosed Ph+ALL
Who this might be right for
Acute Lymphoblastic LeukemiaPhiladelphia ChromosomePhiladelphia-Positive ALL+2 more
Nanfang Hospital, Southern Medical University 67